MINI FUTURE LONG - CHARLES RIVER LABS INTL Share Price

Certificat

DE000PC6FF01

Market Closed - Bid/Ask 19:47:53 15/05/2024 BST After market 20:25:43
7.56 EUR +2.16% Intraday chart for MINI FUTURE LONG - CHARLES RIVER LABS INTL 7.53 -0.40%
Current month+2.78%
1 month-12.22%
Date Price Change
15/05/24 7.56 +2.16%
14/05/24 7.4 +5.41%
13/05/24 7.02 +0.72%
10/05/24 6.97 -3.99%
09/05/24 7.26 -6.08%

Delayed Quote Börse Stuttgart

Last update May 15, 2024 at 07:47 pm

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellCALL
Underlying CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC6FF0
ISINDE000PC6FF01
Date issued 12/03/2024
Strike 152.5 $
Maturity Unlimited
Parity 10 : 1
Emission price 11
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 11.39
Lowest since issue 6.81
Spread 0.1
Spread %1.31%

Company Profile

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Sector
-
More about the company

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Charles River Laboratories International, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
232.8 USD
Average target price
265.6 USD
Spread / Average Target
+14.08%
Consensus